Phase 1 Inflammatory Disease Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
Phase 1 Study to Investigate ABS-101 in Healthy Adult Participants
Chronic Inflammatory Disease
Absci Pty Ltd40 enrolled1 locationACTRN12625000212459
Completed
Phase 1
A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FB102 after single and multiple ascending dose administrations in healthy participants
Autoimmune and Inflammatory Diseases
Forte Biosciences Australia Pty Ltd80 enrolled1 locationACTRN12623001199606
Completed
Phase 1
A Randomised, Double-Blind and Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR9900 after Oral Administrations in Healthy Elderly Volunteers. (Multiple Ascending Dose (MAD), Part 2 Cohort 5).
Inflammatory diseases, particularly in central nervous system
Sironax Aus Pty Ltd10 enrolled1 locationACTRN12623000790640
Completed
Phase 1
A Randomized, Double-Blind and Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR9900 after Oral Administrations in Healthy Adult Volunteers
Inflammatory diseases, particularly in central nervous systemDegenerative diseases, particularly in central nervous system.
Sironax Aus Pty Ltd80 enrolled1 locationACTRN12623000696695
Recruiting
Phase 1
A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of GS-5718 and to Evaluate the Effect of GS-5718 on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
Inflammatory Diseases
Gilead Sciences32 enrolled1 locationACTRN12621000785808
Recruiting
Phase 1
Evaluate the Pharmacokinetics of GS-9876 in Subjects with Impaired Renal Function
Inflammatory Diseases
Gilead Sciences, Inc60 enrolled3 locationsACTRN12616001548426
Completed
Phase 1
Assessing in a sequential manner, the safety, tolerability and pharmacokinetics of multiple formulations of CTP-730 in healthy volunteers
Inflammatory Diseases
CPR Pharma Services22 enrolled1 locationACTRN12615000511538
Recruiting
Phase 1
Ascending multiple doses of a novel Interluken(IL-1) agonist administered to healthy subjects
auto-immune inflammatory disease
Hutchison MediPharma24 enrolled1 locationACTRN12610000287033